Preparation and clinical application of leukocyte-depleted pool platelet concentrates

Objective: To discuss the method of making leukocyte-depleted pool platelet concentrates(LDPPCs),and its safety in clinical application. Methods: Platelet concentrate suspend(PCs) were prepared with the rich plasma method. 7 person's PCs were pooled,decreased white cells and red cells after centrifugation,then transferred suspension of LDPPCs to the specific bags of platelet. Washed it with 0.9% salt solution twice,transferred suspension and added 200ml plasma to make LDPPCs. Using MPV,P-LCR,count,pH and hangover of white and red cells,activation test and adhesive test of platelet,to evaluate the quality change of platelet before and after washing. Randomly selected 32 patients needed to be transfused platelet,and to divide into 2 teams (observation and control).Patients in observation team were transfused 1 cure dosage (platelet count ≥2.5×1011)of LDPPCs,while those in control were transport 1 cure dosage (platelet count ≥2.5×1011)of pheresis platelets. Counted the number of platelet before and after 24 h of transfusion and calculated CCI and recovery rates of platelet. Result: MPV,P-LCR,white and red cells,pH of before and after washing、and stored for 72 h were respectively as: (8.10±0.12),(7.20±0.18),(7.30±0.21)fl;(0.158±0.011)%,(0.146±0.031)%,(0.148±0.024)%,(598.76±803.24)×106,(46.69±60.17)×106,(46.69±60.17)×106;(69.64±49.34)×109,(1.25±1.16)×109,(1.25±1.16)×109;(7.08±0.23),(6.93±0.39),(6.93±0.17)。PAC-1 and adhensive rate of PCs and LDPPCs were respectively as: (2.85±0.42)%,(7.65±0.73)%;(4.65±0.34)%,(4.68±0.51)%。CCI of LDPPCs and pheresis platelets after transfusion 24h were respectively as :(10.56±5.09)and(12.13±8.82)。P-LCR and pH index before and after washing were not different significantly,while MPV,white and red cells were significantly different(P0.05).Conclusion: The various quality index of LDPPCs in this way meets the standards of our country,and it is safe in clinical usage. Its cure effect is indeed,and can be used as supplement to pheresis platelets .